

Karl Malcolm

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3006446/publications.pdf>

Version: 2024-02-01

77
papers

2,631
citations

159525

30
h-index

197736

49
g-index

77
all docs

77
docs citations

77
times ranked

1777
citing authors

#	ARTICLE	IF	CITATIONS
1	In vitro drug release, mechanical performance and stability testing of a custom silicone elastomer vaginal ring releasing dapivirine and levonorgestrel. <i>International Journal of Pharmaceutics</i> , 2022, 4, 100112.	1.2	0
2	Color, Scent and Size: Exploring Women's Preferences Around Design Characteristics of Drug-Releasing Vaginal Rings. <i>AIDS and Behavior</i> , 2022, , 1.	1.4	0
3	The Vaginal Microbiota, Bacterial Biofilms and Polymeric Drug-Releasing Vaginal Rings. <i>Pharmaceutics</i> , 2021, 13, 751.	2.0	13
4	Recent advances in electrospun nanofiber vaginal formulations for women's sexual and reproductive health. <i>International Journal of Pharmaceutics</i> , 2021, 607, 121040.	2.6	8
5	Silicone elastomer formulations for improved performance of a multipurpose vaginal ring releasing dapivirine and levonorgestrel. <i>International Journal of Pharmaceutics</i> : X, 2021, 3, 100091.	1.2	6
6	Use of simulated vaginal and menstrual fluids to model in vivo discolouration of silicone elastomer vaginal rings. <i>International Journal of Pharmaceutics</i> : X, 2021, 3, 100081.	1.2	5
7	Refining the in vitro release test method for a dapivirine-releasing vaginal ring to match in vivo performance. <i>Drug Delivery and Translational Research</i> , 2021, , 1.	3.0	1
8	The ins and outs of drug-releasing vaginal rings: a literature review of expulsions and removals. <i>Expert Opinion on Drug Delivery</i> , 2020, 17, 1519-1540.	2.4	16
9	Towards a dapivirine and levonorgestrel multipurpose vaginal ring: Investigations into the reaction between levonorgestrel and addition-cure silicone elastomers. <i>International Journal of Pharmaceutics</i> , 2019, 569, 118574.	2.6	22
10	Post-use ring weight and residual drug content as potential objective measures of user adherence to a contraceptive progesterone vaginal ring. <i>Contraception</i> , 2019, 100, 241-246.	0.8	7
11	In vitro release testing methods for drug-releasing vaginal rings. <i>Journal of Controlled Release</i> , 2019, 313, 54-69.	4.8	20
12	Dapivirine-releasing vaginal rings produced by plastic freeforming additive manufacturing. <i>International Journal of Pharmaceutics</i> , 2019, 572, 118725.	2.6	47
13	Mechanical testing methods for drug-releasing vaginal rings. <i>International Journal of Pharmaceutics</i> , 2019, 559, 182-191.	2.6	22
14	Drug stability and product performance characteristics of a dapivirine-releasing vaginal ring under simulated real-world conditions. <i>International Journal of Pharmaceutics</i> , 2019, 565, 351-357.	2.6	12
15	Development and pharmacokinetics of a combination vaginal ring for sustained release of dapivirine and the protein microbicide 5P12-RANTES. <i>International Journal of Pharmaceutics</i> , 2019, 564, 207-213.	2.6	8
16	Vaginal rings with exposed cores for sustained delivery of the HIV CCR5 inhibitor 5P12-RANTES. <i>Journal of Controlled Release</i> , 2019, 298, 1-11.	4.8	34
17	Solid state ¹³ C NMR spectroscopy provides direct evidence for reaction between ethinyl estradiol and a silicone elastomer vaginal ring drug delivery system. <i>International Journal of Pharmaceutics</i> , 2018, 548, 689-697.	2.6	11
18	Intravaginal rings for continuous low-dose administration of cervical ripening agents. <i>International Journal of Pharmaceutics</i> , 2018, 549, 124-132.	2.6	10

#	ARTICLE	IF	CITATIONS
19	Impact of ring size and drug loading on the pharmacokinetics of a combination dapivirine-darunavir vaginal ring in cynomolgus macaques. <i>International Journal of Pharmaceutics</i> , 2018, 550, 300-308.	2.6	18
20	Intravaginal immunisation using a novel antigen-releasing ring device elicits robust vaccine antigen-specific systemic and mucosal humoral immune responses. <i>Journal of Controlled Release</i> , 2017, 249, 74-83.	4.8	18
21	Packing Polymorphism of Dapivirine and Its Impact on the Performance of a Dapivirine-Releasing Silicone Elastomer Vaginal Ring. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2015-2025.	1.6	19
22	Pharmacokinetics of the Protein Microbicide 5P12-RANTES in Sheep following Single-Dose Vaginal Gel Administration. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	11
23	Matrix and reservoir-type multipurpose vaginal rings for controlled release of dapivirine and levonorgestrel. <i>International Journal of Pharmaceutics</i> , 2016, 511, 619-629.	2.6	42
24	Sustained release of the candidate antiretroviral peptides T-1249 and JNJ54310516-AFP from a rod insert vaginal ring. <i>Drug Delivery and Translational Research</i> , 2016, 6, 234-242.	3.0	14
25	Controlling levonorgestrel binding and release in a multi-purpose prevention technology vaginal ring device. <i>Journal of Controlled Release</i> , 2016, 226, 138-147.	4.8	31
26	Microbicide vaginal rings: Technological challenges and clinical development. <i>Advanced Drug Delivery Reviews</i> , 2016, 103, 33-56.	6.6	81
27	A Temperature-Monitoring Vaginal Ring for Measuring Adherence. <i>PLoS ONE</i> , 2015, 10, e0125682.	1.1	16
28	Lack of in vitro“in vivo correlation for a UC781-releasing vaginal ring in macaques. <i>Drug Delivery and Translational Research</i> , 2015, 5, 27-37.	3.0	11
29	A novel scalable manufacturing process for the production of hydrogel-forming microneedle arrays. <i>International Journal of Pharmaceutics</i> , 2015, 494, 417-429.	2.6	75
30	Disulfiram-loaded immediate and extended release vaginal tablets for the localised treatment of cervical cancer. <i>Journal of Pharmacy and Pharmacology</i> , 2015, 67, 189-198.	1.2	21
31	A Combination Vaginal Ring Releasing Dapivirine and Darunavir. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A12-A13.	0.5	1
32	Modified Silicone Elastomer Vaginal Gels for Sustained Release of Antiretroviral HIV Microbicides. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 1422-1432.	1.6	20
33	Efficacy of Tenofovir 1% Vaginal Gel in Reducing the Risk of HIV-1 and HSV-2 Infection. <i>Clinical Medicine Insights Women's Health</i> , 2014, 7, CMWH.S10353.	0.6	30
34	Pre-clinical development of a combination microbicide vaginal ring containing dapivirine and darunavir. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2477-2488.	1.3	37
35	Development of disulfiram-loaded vaginal rings for the localised treatment of cervical cancer. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014, 88, 945-953.	2.0	32
36	Vaccine Delivery Systems: Roles, Challenges and Recent Advances. , 2014, , 743-752.		0

#	ARTICLE	IF	CITATIONS
37	The effect of freeze-drying parameters on the cure characteristics of freeze-dried BSA-loaded silicone elastomer. <i>Journal of Applied Polymer Science</i> , 2013, 127, 4402-4408.	1.3	1
38	Preformulation and Development of a Once-Daily Sustained-Release Tenofovir Vaginal Tablet Tablet Containing A Single Excipient. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 1859-1868.	1.6	19
39	Delivering on MPTs: addressing the needs, rising to the challenges and making the opportunities. <i>Contraception</i> , 2013, 88, 321-325.	0.8	14
40	A modified SILCS contraceptive diaphragm for long-term controlled release of the HIV microbicide dapivirine. <i>Contraception</i> , 2013, 88, 58-66.	0.8	39
41	A silicone elastomer vaginal ring for HIV prevention containing two microbicides with different mechanisms of action. <i>European Journal of Pharmaceutical Sciences</i> , 2013, 48, 406-415.	1.9	77
42	Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 678-683.	1.3	53
43	Partial protection against multiple RT-SHIV162P3 vaginal challenge of rhesus macaques by a silicone elastomer vaginal ring releasing the NNRTI MC1220. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 394-403.	1.3	36
44	Sustained Release of the CCR5 Inhibitors CMPD167 and Maraviroc from Vaginal Rings in Rhesus Macaques. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2251-2258.	1.4	60
45	Llama Antibody Fragments Have Good Potential for Application as HIV Type 1 Topical Microbicides. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 198-205.	0.5	30
46	Development of a UC781 releasing polyethylene vinyl acetate vaginal ring. <i>Drug Delivery and Translational Research</i> , 2012, 2, 489-497.	3.0	16
47	Development of polylactide and polyethylene vinyl acetate blends for the manufacture of vaginal rings. <i>Journal of Biomedical Materials Research - Part B Applied Biomaterials</i> , 2012, 100B, 891-895.	1.6	21
48	Characterisation of protein stability in rod-insert vaginal rings. <i>International Journal of Pharmaceutics</i> , 2012, 430, 89-97.	2.6	14
49	Development of liposome gel based formulations for intravaginal delivery of the recombinant HIV-1 envelope protein CN54gp140. <i>European Journal of Pharmaceutical Sciences</i> , 2012, 46, 315-322.	1.9	47
50	Effect of the incorporation of hydroxy-terminated liquid silicones on the cure characteristics, morphology, and release of a model protein from silicone elastomer-covered rods. <i>Journal of Applied Polymer Science</i> , 2012, 124, 805-812.	1.3	5
51	Sustained release of proteins from a modified vaginal ring device. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2011, 77, 3-10.	2.0	48
52	Intravaginal immunization using the recombinant HIV-1 clade-C trimeric envelope glycoprotein CN54gp140 formulated within lyophilized solid dosage forms. <i>Vaccine</i> , 2011, 29, 4512-4520.	1.7	27
53	Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc. <i>Journal of Controlled Release</i> , 2011, 156, 161-169.	4.8	53
54	Pharmacokinetics of UC781-loaded intravaginal ring segments in rabbits: a comparison of polymer matrices. <i>Drug Delivery and Translational Research</i> , 2011, 1, 238-246.	3.0	16

#	ARTICLE	IF	CITATIONS
55	Characterization of silicone elastomer vaginal rings containing HIV microbicide TMC120 by Raman spectroscopy. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 59, 203-207.	1.2	24
56	Freeze-dried, mucoadhesive system for vaginal delivery of the HIV microbicide, dapivirine: Optimisation by an artificial neural network. <i>International Journal of Pharmaceutics</i> , 2010, 388, 136-143.	2.6	48
57	Advances in microbicide vaginal rings. <i>Antiviral Research</i> , 2010, 88, S30-S39.	1.9	158
58	Rheological evaluation of the isothermal cure characteristics of medical grade silicone elastomers. <i>Journal of Applied Polymer Science</i> , 2010, 116, 2320-2327.	1.3	9
59	Controlled-release vaginal ring drug-delivery systems: a key strategy for the development of effective HIV microbicides. <i>Therapeutic Delivery</i> , 2010, 1, 785-802.	1.2	14
60	Development of a microbicide-releasing diaphragm as an HIV prevention strategy. , 2010, 2010, 1089-92.		5
61	Development and evaluation of a vaginal ring device for sustained delivery of HIV microbicides to non-human primates. <i>Journal of Medical Primatology</i> , 2009, 38, 263-271.	0.3	43
62	Persistence of antimicrobial activity through sustained release of triclosan from pegylated silicone elastomers. <i>Biomaterials</i> , 2009, 30, 6739-6747.	5.7	40
63	Characterization of the Rheological, Mucoadhesive, and Drug Release Properties of Highly Structured Gel Platforms for Intravaginal Drug Delivery. <i>Biomacromolecules</i> , 2009, 10, 2427-2435.	2.6	68
64	Vaginal delivery of the recombinant HIV-1 clade-C trimeric gp140 envelope protein CN54gp140 within novel rheologically structured vehicles elicits specific immune responses. <i>Vaccine</i> , 2009, 27, 6791-6798.	1.7	46
65	Safety and Pharmacokinetics of Dapivirine Delivery From Matrix and Reservoir Intravaginal Rings to HIV-Negative Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 416-423.	0.9	142
66	Microbicide delivery: formulation technologies and strategies. <i>Current Opinion in HIV and AIDS</i> , 2008, 3, 558-566.	1.5	35
67	Potential Use of Vaginal Rings for Prevention of Heterosexual Transmission of HIV. <i>American Journal of Drug Delivery</i> , 2006, 4, 7-20.	0.6	29
68	Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide. <i>International Journal of Pharmaceutics</i> , 2006, 325, 82-89.	2.6	139
69	High speed DSC (hyper-DSC) as a tool to measure the solubility of a drug within a solid or semi-solid matrix. <i>International Journal of Pharmaceutics</i> , 2005, 301, 1-5.	2.6	60
70	Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 56, 954-956.	1.3	153
71	Vaginal Microbicides for the Prevention of HIV Transmission. <i>Biotechnology and Genetic Engineering Reviews</i> , 2004, 21, 81-122.	2.4	14
72	Release kinetics of oleyl alcohol from a self-lubricating silicone biomaterial. <i>Journal of Materials Chemistry</i> , 2004, 14, 1093.	6.7	7

#	ARTICLE	IF	CITATIONS
73	Influence of silicone elastomer solubility and diffusivity on the in vitro release of drugs from intravaginal rings. <i>Journal of Controlled Release</i> , 2003, 90, 217-225.	4.8	103
74	In vitro release of nonoxynol-9 from silicone matrix intravaginal rings. <i>Journal of Controlled Release</i> , 2003, 91, 355-364.	4.8	46
75	Self-lubricating silicone elastomer biomaterials. <i>Journal of Materials Chemistry</i> , 2003, 13, 2465.	6.7	26
76	A dynamic mechanical method for determining the silicone elastomer solubility of drugs and pharmaceutical excipients in silicone intravaginal drug delivery rings. <i>Biomaterials</i> , 2002, 23, 3589-3594.	5.7	23
77	Drug Delivery by the Intravaginal Route. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 2000, 17, 47.	1.2	104